US-Funded Hepatitis B Vaccine Trial Cancelled in Guinea-Bissau Amid Ethics Row
Controversial study involving newborns halted after accusations of neocolonialism and unethical research practices.
1Trial Cancellation and Controversy
A proposed study involving 14,000 newborns in Guinea-Bissau was cancelled following intense international criticism. The project, led by the University of Southern Denmark, faced accusations of unethical conduct and neocolonialism. Critics argued that withholding a WHO-recommended hepatitis B vaccine from half the participants in a high-risk region was fundamentally dangerous and morally indefensible.
2The Withholding Protocol
The study design required half of the participating newborns to be denied the hepatitis B vaccine at birth. While the WHO recommends birth-dose vaccination, Guinea-Bissau currently administers it at six weeks. Researchers claimed this gap provided a unique opportunity to study the vaccine's broader health effects before a planned 2028 rollout.
3Local Government and Police Action
Guinea-Bissau authorities prohibited the trial in January, yet reports suggested it might proceed. On October 19, judicial police raided the Bandim Health Project facility in Bissau and seized a batch of vaccines. Health Minister Quinhin Nantote expressed outrage, stating the government was never informed of the study's potential resumption or revised protocols.
4International Health Expert Concerns
Global health experts, including representatives from the WHO, warned that withholding the vaccine exposes infants to chronic infection. With nearly 20% of the population infected, early exposure is a critical risk. Experts questioned why such high-risk research was not conducted in Denmark, labeling the study's methodology as exploitative of vulnerable populations.
5US Funding and Policy Context
The project received $1.6 million in funding from the US government, awarded by the CDC in December 2025. This occurred under the leadership of Health Secretary Robert F. Kennedy Jr., who has expressed skepticism regarding vaccine safety. Critics questioned if the research aimed to support broader US policy shifts regarding newborn immunization schedules.
6University of Southern Denmark Stance
Dean Jakob Grauslund confirmed the trial never commenced and no infants were vaccinated. The university relied on an internal ethics committee approval, despite Danish statutory bodies being unable to review the project. Grauslund maintained that internal approval did not override the mandatory requirement for authorization from Guinea-Bissau’s own national health and legal authorities.
7Hepatitis B Burden in Guinea-Bissau
Hepatitis B remains a severe public health challenge in Guinea-Bissau, with chronic infections leading to liver failure or cancer in up to 25% of cases. The government is currently working with the WHO to accelerate the introduction of a birth-dose vaccine, potentially moving the implementation date forward from 2028 to early next year.
8Broader Implications for Global Research
This incident highlights the growing scrutiny over international research ethics in developing nations. The seizure of materials and the public outcry underscore the tension between academic research objectives and the protection of vulnerable populations. Moving forward, international health organizations are emphasizing the necessity of transparent, locally-approved protocols for all medical trials.